Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 18/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746431 | 0.89 | GRIA2 (1.00) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL3134820 | 0.87 | GRIA2 (1.00) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL4753813 | 0.86 | GRIA2 (0.98) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL3126029 | 0.84 | GRIA2 (0.96) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL4744138 | 0.80 | GRIA2 (0.76) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL4744375 | 0.80 | GRIA2 (0.77) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL3129977 | 0.79 | GRIA2 (0.80) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL4751483 | 0.78 | GRIA2 (0.82) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL1423665 | 0.77 | GRIA2 (0.78) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL1423601 | 0.77 | GRIA2 (0.78) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008110566-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | WO | disclosed |